# Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

> **NCT01604057** · PHASE2 · UNKNOWN · sponsor: **Azelon Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Osteoporosis
- Osteopenia

## Interventions

- **DRUG:** ZT-034 Low Dose Nasal Spray
- **DRUG:** ZT-034 Mid Dose Nasal Spray
- **DRUG:** ZT-034 High Dose Nasal Spray
- **DRUG:** Teriparatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01604057
- **Lead sponsor:** Azelon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604057, "Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01604057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*